Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of ceftobiprole medocaril versus daptomycin for Staphylococcus aureus bacteremia including infective endocarditis
MOH_2019-01-10_003595Phase 3Recruiting
- Sponsor
- Basilea Pharmaceutica
- Start
- Sep 2018
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Staphylococcal bacteremia and endocarditis (IE) comparing ceftobiprole medocaril with daptomycin (2 arms). Started Sep 2018; status: recruiting.
02
Drugs
ceftobiprole medocarildaptomycin
03
Conditions
Staphylococcal bacteremiaendocarditis (IE)
Beyond the preview
Go deeper on MOH_2019-01-10_003595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-01-10_003595.